Patient Characteristics
| Characteristics | Safety set | Immunologic set |
|---|---|---|
| n = 12 | n = 11 | |
| Age in years, median (range) | 48 (31, 62) | 49 (31, 62) |
| n (%) | n (%) | |
| Gender | ||
| Female | 12 (100%) | 11 (100%) |
| Race | ||
| Caucasian | 12 (100%) | 11 (100%) |
| Ethnicity | ||
| Non-Hispanic | 12 (100%) | 11 (100%) |
| Menopausal Status | ||
| Post-menopausal | 8 (67%) | 7 (64%) |
| Pre-menopausal | 4 (33%) | 4 (33%) |
| Pathologic Type | ||
| Ductal | 11 (92%) | 11 (100%) |
| Unknown | 1 (8%) | |
| Histologic Grade | ||
| Grade II | 3 (25%) | 3 (27%) |
| Grade III | 8 (67%) | 7 (64%) |
| Unknown | 1 (8%) | 1 (9%) |
| Stage | ||
| II | 3 (25%) | 3 (27%) |
| III | 9 (75%) | 8 (73%) |
| ER Status | ||
| Negative | 5 (42%) | 5 (45%) |
| Positive | 7 (58%) | 6 (55%) |
| PR Status | ||
| Negative | 6 (50%) | 6 (55%) |
| Positive | 6 (50%) | 5 (45%) |
| Her 2/Neu Status | ||
| Negative | 6 (50%) | 5 (45%) |
| Positive | 5 (42%) | 5 (45%) |
| Unknown | 1 (8%) | 1 (9%) |
| On Hormonal Therapy | ||
| No | 6 (50%) | 5 (45%) |
| Yes | 6 (50%) | 6 (55%) |
| Type | ||
| Arimidex | 3 | 3 |
| Tamoxifen | 3 | 3 |
| HLA type (may be multiple) | ||
| A1 | 7 (58%) | 7 (64%) |
| A2 | 5 (42%) | 4 (36%) |
| A3 | 6 (50%) | 6 (55%) |